Micromotor-enabled active drug delivery for in vivo treatment of stomach infection

Berta Esteban-Fernández de Ávila, Pavimol Angsantikul, Jinxing Li, Miguel Angel Lopez-Ramirez, Doris E. Ramírez-Herrera, Soracha Thamphiwatana, Chuanrui Chen, Jorge Delezuk, Richard Samakapiruk, Valentin Ramez, Marygorret Obonyo, Liangfang Zhang () and Joseph Wang ()
Additional contact information
Berta Esteban-Fernández de Ávila: University of California San Diego
Pavimol Angsantikul: University of California San Diego
Jinxing Li: University of California San Diego
Miguel Angel Lopez-Ramirez: University of California San Diego
Doris E. Ramírez-Herrera: University of California San Diego
Soracha Thamphiwatana: University of California San Diego
Chuanrui Chen: University of California San Diego
Jorge Delezuk: University of California San Diego
Richard Samakapiruk: University of California San Diego
Valentin Ramez: University of California San Diego
Marygorret Obonyo: University of California San Diego
Liangfang Zhang: University of California San Diego
Joseph Wang: University of California San Diego

Nature Communications, 2017, vol. 8, issue 1, 1-9

Abstract: Abstract Advances in bioinspired design principles and nanomaterials have led to tremendous progress in autonomously moving synthetic nano/micromotors with diverse functionalities in different environments. However, a significant gap remains in moving nano/micromotors from test tubes to living organisms for treating diseases with high efficacy. Here we present the first, to our knowledge, in vivo therapeutic micromotors application for active drug delivery to treat gastric bacterial infection in a mouse model using clarithromycin as a model antibiotic and Helicobacter pylori infection as a model disease. The propulsion of drug-loaded magnesium micromotors in gastric media enables effective antibiotic delivery, leading to significant bacteria burden reduction in the mouse stomach compared with passive drug carriers, with no apparent toxicity. Moreover, while the drug-loaded micromotors reach similar therapeutic efficacy as the positive control of free drug plus proton pump inhibitor, the micromotors can function without proton pump inhibitors because of their built-in proton depletion function associated with their locomotion.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-017-00309-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00309-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-00309-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().